ZZ Biotech

ZZ Biotech LLC, founded in Houston, TX, is a clinical-stage biopharmaceutical company dedicated to developing innovative biologic treatments for ischemic stroke and other neurological diseases. The company's core mission is to advance healthcare through cutting-edge research and development of therapies that address critical unmet medical needs. ZZ Biotech's flagship product, 3K3A-APC, is designed to provide neuroprotection and improve outcomes for stroke patients. Their market focus includes hospitals, healthcare providers, and research institutions involved in neurological care.

Notable affiliated individuals include leading scientists and clinicians in the field of neurology who contribute their expertise to the company's research initiatives. Key investors are typically venture capital firms specializing in healthcare and biotech innovations. ZZ Biotech has achieved significant milestones, including successful clinical trials demonstrating the efficacy of 3K3A-APC. The company’s impact is marked by its potential to transform stroke treatment protocols and improve patient recovery rates, positioning it as a pivotal player in the biopharmaceutical industry.